ATE205402T1 - Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten - Google Patents

Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten

Info

Publication number
ATE205402T1
ATE205402T1 AT98932358T AT98932358T ATE205402T1 AT E205402 T1 ATE205402 T1 AT E205402T1 AT 98932358 T AT98932358 T AT 98932358T AT 98932358 T AT98932358 T AT 98932358T AT E205402 T1 ATE205402 T1 AT E205402T1
Authority
AT
Austria
Prior art keywords
inhibitor
aldosereductase
compositions containing
ace
diabetic
Prior art date
Application number
AT98932358T
Other languages
English (en)
Inventor
Frank Carey
David Patrick Tuffin
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE205402T1 publication Critical patent/ATE205402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98932358T 1997-07-08 1998-07-02 Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten ATE205402T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714274.9A GB9714274D0 (en) 1997-07-08 1997-07-08 Pharmaceutical composition
PCT/GB1998/001959 WO1999002189A1 (en) 1997-07-08 1998-07-02 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor

Publications (1)

Publication Number Publication Date
ATE205402T1 true ATE205402T1 (de) 2001-09-15

Family

ID=10815469

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98932358T ATE205402T1 (de) 1997-07-08 1998-07-02 Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten

Country Status (28)

Country Link
US (1) US6337327B1 (de)
EP (1) EP0991424B1 (de)
JP (1) JP2002509540A (de)
KR (1) KR20010015551A (de)
CN (1) CN1186097C (de)
AT (1) ATE205402T1 (de)
AU (1) AU746211B2 (de)
BR (1) BR9810570A (de)
CA (1) CA2292451A1 (de)
CZ (1) CZ290276B6 (de)
DE (1) DE69801661T2 (de)
DK (1) DK0991424T3 (de)
ES (1) ES2163283T3 (de)
GB (1) GB9714274D0 (de)
HK (1) HK1028876A1 (de)
HU (1) HU224009B1 (de)
ID (1) ID24597A (de)
IL (1) IL133004A (de)
NO (1) NO20000045D0 (de)
NZ (1) NZ501165A (de)
PL (1) PL337925A1 (de)
PT (1) PT991424E (de)
RU (1) RU2216354C2 (de)
SK (1) SK122000A3 (de)
TR (1) TR199903026T2 (de)
UA (1) UA64761C2 (de)
WO (1) WO1999002189A1 (de)
ZA (1) ZA985993B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) * 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
WO2003046165A1 (en) * 2001-11-26 2003-06-05 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
ES2633766T3 (es) 2011-10-28 2017-09-25 Lumena Pharmaceuticals Llc Inhibidores de reciclaje de ácido biliar para el tratamiento de enfermedades de hígado colestático pediátrico
US20150197536A1 (en) * 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN103063794B (zh) * 2012-12-24 2014-08-06 扬子江药业集团南京海陵药业有限公司 一种依帕司他片的含量检测控制方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications

Also Published As

Publication number Publication date
HUP0002644A2 (hu) 2000-12-28
CN1186097C (zh) 2005-01-26
AU8229698A (en) 1999-02-08
UA64761C2 (uk) 2004-03-15
NO20000045L (no) 2000-01-06
GB9714274D0 (en) 1997-09-10
AU746211B2 (en) 2002-04-18
CZ290276B6 (cs) 2002-06-12
DK0991424T3 (da) 2001-12-03
DE69801661D1 (de) 2001-10-18
SK122000A3 (en) 2000-06-12
KR20010015551A (ko) 2001-02-26
WO1999002189A1 (en) 1999-01-21
HK1028876A1 (en) 2001-03-09
ZA985993B (en) 1999-01-18
TR199903026T2 (xx) 2000-04-21
RU2216354C2 (ru) 2003-11-20
EP0991424A1 (de) 2000-04-12
NO20000045D0 (no) 2000-01-06
US6337327B1 (en) 2002-01-08
JP2002509540A (ja) 2002-03-26
HU224009B1 (hu) 2005-04-28
ES2163283T3 (es) 2002-01-16
DE69801661T2 (de) 2002-07-04
NZ501165A (en) 2001-06-29
ID24597A (id) 2000-07-27
IL133004A (en) 2004-12-15
PT991424E (pt) 2002-02-28
CZ200017A3 (cs) 2000-05-17
PL337925A1 (en) 2000-09-11
IL133004A0 (en) 2001-03-19
EP0991424B1 (de) 2001-09-12
CA2292451A1 (en) 1999-01-21
BR9810570A (pt) 2000-09-19
CN1261804A (zh) 2000-08-02

Similar Documents

Publication Publication Date Title
NO20061736L (no) Krystallform av epotilon B
DE69501591D1 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
ATE205402T1 (de) Zusammensetzungen welche ein ace-hemmer und ein aldosereductasehemmer enthalten
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
TR200001451T2 (tr) Aldoz redüktaz önleyici ve glikojen fosforilaz önleyici kombinasyonu.
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
BR0107691A (pt) Sapogeninas substituìdas e seu uso
TR199801930T2 (xx) 6-Fenilpiridil-2-amin t�revleri.
BR0215405A (pt) Composições e processos de uso de collajolie
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
DE69905170T2 (de) Thiazolopyrimidinderivate
PL373465A1 (en) Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives
WO2004043362A3 (en) Acyl guanidine compounds and use thereof
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE60116106D1 (de) Benzofuran derivate und ihre verwendung als antibakterielle wirkstoffe
TR200100637T2 (tr) Yeni doğal ürün türevleri
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE469146T1 (de) Benzofuranderivate und deren verwendung bei der behandlung von mikrobiellen infektionen
GB9723824D0 (en) Cytostatic agents
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee